Drug treatment of cardiac arrhythmias is not uniformly effectiveand frequently causes side effects. Recently, new data havebecome available that more clearly delineate the risks of antiarrhythmic-drugtherapy. At the same time, establishing a benefit of treatmentwith these drugs has proved difficult. The potential benefitsof antiarrhythmic therapy -- reductions in mortality or in symptomsrelated to arrhythmias -- as well as the potential risks areoutlined in Table 1. In this review I shall consider the availabledata defining these risks and benefits (which have usually beendelineated in specific groups of patients using specific drugs),. . . [Full Text of this Article]
Effects of Antiarrhythmic Therapy on Mortality
Effects of Antiarrhythmic Drugs on Arrhythmia-Related Symptoms
Provocation of Arrhythmias by Antiarrhythmic Drugs
Torsade de Pointes
Incessant Ventricular Tachycardia
Other Risks of Antiarrhythmic-Drug Therapy
An Approach to the Treatment of Arrhythmias
Whom to Treat for Specific Arrhythmias
Minimizing the Risks of Antiarrhythmic Therapy
Future Trends in Antiarrhythmic Therapy
Source Information
From the Division of Clinical Pharmacology, Vanderbilt University, 532C Medical Research Bldg., Nashville, TN 37232-6602, where reprint requests should be addressed to Dr. Roden.
References
This article has been cited by other articles:
Andersen, S. S., Hansen, M. L., Gislason, G. H., Schramm, T. K., Folke, F., Fosbol, E., Abildstrom, S. Z., Madsen, M., Kober, L., Torp-Pedersen, C.
(2009). Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace
11: 886-891
[Abstract][Full Text]
Hansen, M. L., Gadsboll, N., Gislason, G. H., Abildstrom, S. Z., Schramm, T. K., Folke, F., Friberg, J., Sorensen, R., Rasmussen, S., Poulsen, H. E., Kober, L., Madsen, M., Torp-Pedersen, C.
(2008). Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace
10: 395-402
[Abstract][Full Text]
Collins, H. L., DiCarlo, S. E.
(2005). Acute exercise increases the ventricular arrhythmia threshold via the intrinsic adenosine receptor system in conscious hypertensive rats. Am. J. Physiol. Heart Circ. Physiol.
289: H1020-H1026
[Abstract][Full Text]
Canyon, S. J., Dobson, G. P.
(2004). Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am. J. Physiol. Heart Circ. Physiol.
287: H1286-H1295
[Abstract][Full Text]
McNamara, R. L., Tamariz, L. J., Segal, J. B., Bass, E. B.
(2003). Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. ANN INTERN MED
139: 1018-1033
[Abstract][Full Text]
Kasliwal, R. R, Mukesh, S., Manohar, G., Aggarwal, N., Bhatia, A.
(2003). Pharmacotherapy of Atrial Fibrillation. Asian Cardiovasc. Thorac. Ann.
11: 364-374
[Abstract][Full Text]
Rolf, S., Bruns, H.-J., Wichter, T., Kirchhof, P., Ribbing, M., Wasmer, K., Paul, M., Breithardt, G., Haverkamp, W., Eckardt, L.
(2003). The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol. Eur Heart J
24: 1104-1112
[Abstract][Full Text]
Al-Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., Califf, R. M.
(2003). What Clinicians Should Know About the QT Interval. JAMA
289: 2120-2127
[Abstract][Full Text]
Wellens, H. J.J.
(2002). Contemporary Management of Atrial Flutter. Circulation
106: 649-652
[Full Text]
Plewan, A.
(2002). A reply. Eur Heart J
23: 586-586
[Full Text]
Darpo, B.
(2001). Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl
3: K70-K80
[Abstract]
Plewan, A, Lehmann, G, Ndrepepa, G, Schreieck, J, Alt, E.U, Schomig, A, Schmitt, C
(2001). Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Sotalol vs bisoprolol. Eur Heart J
22: 1504-1510
[Abstract]
Zebe, H.
(2000). Atrial fibrillation in dialysis patients. Nephrol Dial Transplant
15: 765-768
[Full Text]
Kreiss, Y., Sidi, Y., Gur, H.
(1999). Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department. Postgrad. Med. J.
75: 278-281
[Abstract][Full Text]
Yong, S. L., Xu, R., McLarnon, J. G., Zolotoy, A. B., Beatch, G. N., Walker, M. J. A.
(1999). RSD1000: A Novel Antiarrhythmic Agent with Increased Potency under Acidic and High-Potassium Conditions. J. Pharmacol. Exp. Ther.
289: 236-244
[Abstract][Full Text]
Chung, M. K., Schweikert, R. A., Wilkoff, B. L., Niebauer, M. J., Pinski, S. L., Trohman, R. G., Kidwell, G. A., Jaeger, F. J., Morant, V. A., Miller, D. P., Tchou, P. J.
(1998). Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?: yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol
32: 169-176
[Abstract][Full Text]
Grace, A. A., Camm, A. J.
(1998). Quinidine. NEJM
338: 35-45
[Full Text]
Sweeney, M. O., Ruskin, J. N., Garan, H., McGovern, B. A., Guy, M. L., Torchiana, D. F., Vlahakes, G. J., Newell, J. B., Semigran, M. J., Dec, G. W.
(1995). Influence of the Implantable Cardioverter/Defibrillator on Sudden Death and Total Mortality in Patients Evaluated for Cardiac Transplantation. Circulation
92: 3273-3281
[Abstract][Full Text]
Pinski, S. L., Fahy, G. J.
(1995). The Proarrhythmic Potential of Implantable Cardioverter-Defibrillators. Circulation
92: 1651-1664
[Abstract][Full Text]
Gillis, A. M., Sheldon, R. S., Wyse, D. G., Leitch, J. W., Yee, R., Klein, G. J., Duff, H. J., Mitchell, L. B.
(1995). Long-term Reproducibility of Ventricular Tachycardia Induction in Patients With Implantable Cardioverter/Defibrillators : Serial Noninvasive Studies. Circulation
91: 2605-2613
[Abstract][Full Text]
Previous
